Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Benefit of allo SCT for MCL offset by increased risk of mortality, GVHD

Key clinical point: Transplant type was identified as an independent risk factors for improved overall survival (OS).

Major finding: Auto stem cell transplantation (SCT) showed improved OS: HR 0.35, P < .05, compared to allo SCT.

Study details: Single center study of 56 patients who underwent transplant as consolidation therapy for MCL.

Disclosures: Study funding, authors conflicts not reported.